could go either way. The way I see it, if it is good (or great) that will be the end for the shorts immediately as sales and profits will only get better over the next months and years.
If the first quarterly report that includes Lymphoseek sales does not live up to expectations, it will VERY LIKELY improve over the next two consecutive quarters. Some products in many markets get off to a slow start for a host of reasons. Most of us believe Lymphoseek will soon be the STANDARD of care so as it is, the first sales report IF GOOD may mean GAME OVER for the SHORTS.